NASDAQ · DRUG
Bright Minds Biosciences Inc.
$55.80-$0.89 (-1.57%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.79% below the high.
Loading market information…
NASDAQ · HSTO · USD
Stock price, earnings
Quote as of Nov 25, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Histogen Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $3.76M-40.17% vs estimate |
| Q4 2021 | Mar 10, 2022 | -$1.40+36.36% vs estimate | $5.00K |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$55.80-$0.89 (-1.57%)
Bright Minds Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.79% below the high.
$2.98-$0.14 (-4.49%)
Entera Bio Ltd.’s quoted price sits in the upper half of its reported 52-week range, 29.05% below the high.
$3.23$0.00 (0.0%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$1.16-$0.03 (-2.86%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.58% below the high.
$1.02+$0.09 (+9.68%)
YS Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.7% below the high.
$5.05-$0.23 (-4.45%)
Tonix Pharmaceuticals Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.46% below the high.
$4.94-$0.25 (-4.82%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.45% below the high.
$2.11+$0.18 (+9.33%)
Aileron Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.56% below the high.
